Category: Uncategorized
-
Centre caps trade margins on non-scheduled cancer drugs at 30%, expects ₹2,500 crore annual savings for patients
The government expects to reduce prices of the non-scheduled cancer drugs by up to 70% through the move and help patients save ₹2,500 crore annually.
-
Centre caps trade margins on non-scheduled cancer drugs at 30%, expects ₹2,500 crore annual savings for patients
The government expects to reduce prices of the non-scheduled cancer drugs by up to 70% through the move and help patients save ₹2,500 crore annually.
-
Centre caps trade margins on non-scheduled cancer drugs at 30%, expects ₹2,500 crore annual savings for patients
The government expects to reduce prices of the non-scheduled cancer drugs by up to 70% through the move and help patients save ₹2,500 crore annually.
-
Centre caps trade margins on non-scheduled cancer drugs at 30%, expects ₹2,500 crore annual savings for patients
The government expects to reduce prices of the non-scheduled cancer drugs by up to 70% through the move and help patients save ₹2,500 crore annually.
-
Centre caps trade margins on non-scheduled cancer drugs at 30%, expects ₹2,500 crore annual savings for patients
The government expects to reduce prices of the non-scheduled cancer drugs by up to 70% through the move and help patients save ₹2,500 crore annually.
-
Centre caps trade margins on non-scheduled cancer drugs at 30%, expects ₹2,500 crore annual savings for patients
The government expects to reduce prices of the non-scheduled cancer drugs by up to 70% through the move and help patients save ₹2,500 crore annually.
-
Centre caps trade margins on non-scheduled cancer drugs at 30%, expects ₹2,500 crore annual savings for patients
The government expects to reduce prices of the non-scheduled cancer drugs by up to 70% through the move and help patients save ₹2,500 crore annually.
-
Centre caps trade margins on non-scheduled cancer drugs at 30%, expects ₹2,500 crore annual savings for patients
The government expects to reduce prices of the non-scheduled cancer drugs by up to 70% through the move and help patients save ₹2,500 crore annually.
-
Firmus pulls biggest ASX float since Telstra amid investor doubt about datacentre company
The $11-a-share offer would have been the biggest debut on the stock market since the telecommunication giant in 1997 Get our breaking news email, free app or daily news podcast Firmus Technologies has scrapped what was set to be Australia’s biggest company listing in decades after investor demand for its much-hyped AI datacentre business failed…
Latest News
Stay Connected
Categories
Business Health India Politics Science Sports Technology Uncategorized World
Tags
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
